ArticleCureus2025
Antimicrobial Susceptibility of Ceftazidime-Avibactam in Clinical Isolates of Carbapenemase-Producing Enterobacterales.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbapenem resistance in community-acquired urinary tract infections caused byJAC-antimicrobial resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenemase-producing Enterobacterales (CPE) are a major threat to public health around the world due to their extensive drug resistance mechanism. Ceftazidime-avibactam has emerged as a drug of choice for treating carbapenemase-producing organisms.
objectiveIn this study, we aimed to evaluate the antimicrobial susceptibility of ceftazidime-avibactam against METHODOLOGY: It was a cross-sectional study, and data was collected over a period of six months in the Department of Microbiology, in a tertiary care teaching hospital of Southern Rajasthan. One hundred fifty clinical isolates, which were resistant to one of the carbapenems (imipenem, meropenem, or ertapenem) by the Kirby-Bauer disk diffusion method, were included in the study. All these isolates were subjected to carbapenemase detection by phenotypic methods, i.e., modified carbapenem inactivation method (mCIM) and ethylenediaminetetraacetic acid (EDTA)-carbapenem inactivation method (eCIM), and the results were analyzed to find out carbapenemase production as per Clinical and Laboratory Standards Institute (CLSI) 2023. Ceftazidime-avibactam susceptibility was determined using E-strips, and synergy with aztreonam was evaluated using disk approximation method.
resultsAmong 150 isolates, 142 (94.7%) were confirmed as carbapenemase producers. Class A carbapenemases were detected in 89 (62.7%) isolates, class B MBLs in 38 (26.8%) isolates, and 15 (10.5%) showed mixed carbapenemase production. Ceftazidime-avibactam was effective against 87.6% of class A carbapenemase producers but only 15.8% against MBL producers. The combination of ceftazidime-avibactam and aztreonam showed synergistic activity in 84.2% of MBL-producing isolates.
conclusionCeftazidime-avibactam shows excellent activity against class A carbapenemase-producing Enterobacterales but limited efficacy against MBL producers. The combination with aztreonam significantly enhances activity against MBL-producing strains which suggests a possible way to treat infections caused by these tough bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.